Floatz logo

Picoplatin

Lymphoma

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

289 Active assets in the Lymphoma cohort.

View all 50

Same molecule, other indications

Picoplatin is also rated in:

small cell lung carcinomaDormant
B
Indicative ·
56 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
52 / 100
View asset →
Hormone Refractory Prostate CancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →